Carroll SM, Wasiak R. Patient Access Systems – the use of risk sharing in the UK. Healthy Value, 2009; 12 (7):A286 – A287.www.valueinhealthjournal.com/article/S1098-3015 (10) 74405-3/pdf. Access on April 13, 2015. Results-based agreements also offer the opportunity to develop data on a given population. This data could provide the manufacturer and supplier with insight into how it continues to operate one of its respective abs competitors. To the extent that a manufacturer can learn how well its product works with a given subpopulation, it can use this information in future negotiations with other suppliers and payers. Similarly, suppliers can use their knowledge to demonstrate a better quality of supply for their specific populations, which is increasingly important in the rapidly consolidating market. Price volume agreements are the most common and performance-based agreements are emerging and are expected to be more common in the future, which is probably related to the development of personalized medicine. The administrative complexity associated with these agreements and the need to change the legal and regulatory framework are seen as major obstacles to their wider use. It should be noted that the level of use of risk-sharing agreements was high, with 90% of respondents saying that they currently had such a contract with a pharmaceutical company and that they wanted to renew or sign new ones (96%).
In addition, 25% of those who did not have such an agreement expressed interest in signing such an agreement in the near future. The duration of the contracts was about one year (97% of respondents); Half of them felt that the duration of the agreement was not a precondition for their feasibility. Of those who said they did not have a risk-sharing agreement, half said they would make clinical and administrative management of drugs more complex and not effective tools. Cheema PK, Gavura S, Godman B, Yeung L, Trudeau ME. Global differences in the reimbursement of new cancer drugs: improved access through risk-sharing agreements. J Clin Oncol. 2010; 28 (15_suppl): 6050. ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.6050. Access on April 13, 2015. Cook JP, Vernon YES, Manning R. Pharmaceutical Risk-Sharing-Sharing. Pharmacoeconomics.
2008;26(7):551-6. Definitions and other names Risk-sharing agreements are known by several names: Managed Entry Schemes (MES), Outcomes Based Schemes, Risk-Sharing Agreements, Coverage with Evidence Development, Access with Evidence Development, Patient Access Schemes Condition, Licensing, Pay for Performance Programs, et cetera. However, the common denominator of these agreements is that the contract addresses an explicitly perceived cost risk and that the obligation to define the risk between payers and manufacturers is accepted in a definite manner. Neumann PJ. Where are we in risk-sharing agreements? Health value. 2013;16:701–2. Over the past two decades, public health systems have put in place several management tools to cope with the increasing pressure of pharmaceutical companies to introduce new products, usually at high prices, in a context of uncertainty and budgetary constraints.
